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Background: Neurodegenerative disorders such Alzheimer's disease (AD) are often characterized by senile plaques
and neurofibrillary tangle. In addition, reactive astrogliosis, microglia activation and a chronic inflammation are
found in AD brain. Activated microglia has been reported to express a large number of beta chemokines including
monocyte chemoattractant protein-1 (MCP-1). The potential role of MCP-1 in AD pathogenesis is supported by the
over expression of MCP-1 associated with an increase of amyloid deposition in transgenic mice. MCP-1 protein may
be regulated by a single nucleotide polymorphism (SNP) occurring at position −2518 of the MCP-1 gene promoter.
In this paper we correlated the A-2518G MCP-1 SNP distribution in three different populations: AD, control and MCI
(mild cognitive impairment) population to evaluate whether this SNP might be a risk factor for AD or for MCI-AD
conversion. MCP-1 plasma levels were also measured and correlated to the cognitive impairment (CIND) and AD risk.
Results: No differences in genotype distribution and allele frequencies of A-2518G MCP-1 SNP among AD patients,
MCI subjects and controls were observed even after APOEe4 variation adjustment with logistic regression. However in
MCI subjects, followed up for two years, this SNP appears to influence the progression of the disease; being the G allele
slightly more frequent in MCI patients that developed AD. MCP-1 plasma levels were different among CIND (cognitive
impairment but no dementia), AD and controls. The MCP-1 A-2518G promoter polymorphism did not affect MCP-1
plasma levels within the three populations.
Conclusions: MCP-1 G allele did not affect the risk of AD, but slightly influenced MCI conversion to AD and MCP-1
plasma levels were increased in subjects with preclinical AD.
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Alzheimer’s disease (AD) is the most common form of
adult-onset dementia. Pathological hallmarks of AD
include amyloid deposits rich in β-amyloid (Aβ) peptide,
neurofibrillary tangles composed of hyperphosphorylated
tau and the occurrence of activated microglia [1].
Etiopathogenetic mechanisms associated with age-
related cognitive decline and AD are complex and still
largely unclear. However, both genetic and environmen-
tal factors are implicated in the pathogenesis of the
disease [2-5].* Correspondence: elisa.porcellini3@unibo.it
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reproduction in any medium, provided the orA substantial literature has suggested the involvement
of several processes in AD onset, such as inflammation,
plaque deposition, oxidative stress, cholesterol homeo-
stasis and endothelial dysfunction [6-9].
A number of inflammatory mediators associated with
amyloid deposits such as Interleukin-1 (IL-1), IL-6,
transforming growth factor (TGF-β), TNF-α, acute phase
proteins for instance α−1 antichymotrypisn (ACT) and
α2-macroglobulin, and several complement factors have
been detected in AD brains [10,11].
Inflammatory cytokines are produced by activated
microglia and astrocytes and these molecules are able to
stimulate the phagocitic activity of microglia [12]. Acti-
vated microglia has been reported to express a large
number of beta chemokines including monocyte chemo-
attractant protein-1 (MCP-1) [13,14].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Genotype distribution and allele frequency of the
A-2518G MCP-1 promoter polymorphism in patients with
probable AD, patients with MCI and controls (CTR) from
Northern Italy
AA AG GG Allele A Allele G
(n) % (n) % (n) % (n) % (n) %
AD (n=291) (139) 47.8 (130) 44.7 (22) 7.6 (269) 92.4 (152) 52.2
MCI(n=88) (49) 55.7 (37) 42.0 (2) 2.3 (86) 97.7 (38) 43.2
CTR(n=146) (69) 47.3 (66) 45.2 (11) 7.5 (135) 92.5 (77) 52.7
Statistics.
AD vs CTR (genotypic distribution): Pearson χ2= 0.11, p=0.994;
logistic regression adjusted for age and APOE e4 p=0.713 c.i
95% (0.981-1.013).
CTR vs MCI (genotypic distribution): Pearson χ2= 3.633, p=0.163;
logistic regression adjusted for age and APOE e4 p=0.988 c.i
95% (0.970-1.007).
AD vs MCI (genotypic distribution): Pearson χ2= 3.942, p=0.139;
logistic regression adjusted for age and APOE e4 p=0.299 c.i
95% (0.994-1.018).
Figure 1 MCP-1 A-2518G promoter polymorphism (rs699947)
pattern after O/N digestion with PvuII enzyme. Digestion
resolved three different band patterns, according to the three
different genotypes; e.g. at 222 bp and 705 bp (GG genotype),
222 bp, 705 bp and 927 bp (GA genotype) or only 927 bp (AA
genotype). 100 bp Molecular weight (MW) and Negative control
(NC) were also indicated in agarose gel.
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mokine that, by regulating monocyte chemotaxis and
endothelial activation, modulates inflammatory pro-
cesses. The potential role of MCP-1 in AD pathogenesis
is supported by the over expression of MCP-1 associated
with an increase of Abeta deposition in Amyloid precur-
sor protein (APP) transgenic mice [15]. In addition
higher MCP-1 levels in cerebro spinal fluid (CSF) of AD
patients than matched controls have been reported [16].
This latter finding has been confirmed by an indepen-
dent recent study showing that CSF levels of MCP-1
were significant increased in subjects with AD compared
to healthy controls [17]. Moreover, a recent study
showed that elevated MCP-1 CSF levels were associated
with an higher annual decrease of MMSE score in AD
patients; these findings suggested that elevated CSF
MCP-1 was associated with an accelerated rate of cogni-
tive decline [18].
Data regarding MCP-1 plasma levels are conflicting.
Several Authors showed that MCP-1 levels were elevated
in AD patients or subjects with mild cognitive impair-
ment (MCI) [19,20]. These data were not confirmed by
other studies reporting no association between MCP-1
plasma levels and AD [12,21].
It has been shown that serum levels and biological
activity of the MCP-1 protein may be regulated by a
single nucleotide polymorphism (SNP) occurring at
position −2518 of the MCP-1 gene promoter [22,23].
Several studied described this SNP as a risk factor for
AD but results are not always concordant being this
polymorphism differentially distributed in different po-
pulations [21,24-27].
Here we present data on MCP-1 A-2518G polymor-
phism in AD patients, in subjects with MCI and in a
healthy elderly control population and its association
with the risk of AD or MCI.
MCP-1 plasma levels were also measured in AD
patients, subjects with cognitive impairment but no
dementia (CIND) and healthy elderly followed up for
five years and levels of MCP-1 were correlated with
cognitive deterioration.
Results
As reported in Table 1, no difference in genotype distri-
bution and allele frequencies of A-2518G MCP-1 SNP
among AD patients, MCI subjects and controls (CTR)
were observed (AD vs CTR χ2= 0.11, p=0.994; CTR vs
MCI χ2= 3.633, p=0.163; AD vs MCI χ2= 3.942,
p=0.139). An agarose gel with the three different pattern
of bands (representing the three different genotypes)
was showed in Figure 1.
Logistic regression analysis regarding MCP-1 genotype
distribution adjusted for age and APOEe4 was applied
to these populations and results were not statisticallysignificant; therefore age and APOEε4 presence did not
affect MCP-1 genotype distribution (AD vs CTR
p=0.713, AD vs MCI p=0.299, MCI vs CTR p=0.988)
and MCP-1 genotype was not an independent risk factor
for AD or MCI.
MCI patients were followed up for 2 years and cogni-
tive performances were detected at the end of the study.
Among the MCI group, 38 subjects evolved to AD, and
45 did not. Genotype distribution and allele frequency of
MCI patients converting to AD compared to those
remaining MCI were described in Table 2. The G allele
was slightly more frequent in MCI patients that
converted to AD after 2 years than in those remaining
Table 2 Genotype distribution and allele frequency of MCI patients converting to AD compared to those remaining
MCI
AA (n) % AG (n) % GG (n) % Allele A (n) % Allele G (n) %
MCI->AD (n=38) (19) 50.0 (18) 47.4 (1) 2.4 (37) 97.4 (19) 47.4
MCI= MCI (n=45) (28) 62.2 (17) 37.8 (0) 0 (45) 100 (17) 37.8
Pearson χ2 = 2.117, p= 0.337.
Logistic regression analysis adjusted for Age and APOE e4 : G allele p=0.137 c.i 95% (0.948-1.007).
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cant (χ2 = 2.117, p= 0.337). This difference was not
statistically significant also after logistic regression ad-
justed for age and APOEε4 presence (p=0.137).
MCP-1 plasma levels were also detected in AD patients
(n=87), controls (n=34) and CIND subjects (n=24), as
shown in Figure 2.
AD patients showed lower MCP-1 levels (43 pg/ml ± 28 )
than CIND (88 pg/ml ± 38) and controls (66 pg/ml ± 50),
differences in MCP-1 levels among the three groups were
statistically significant and elevated in CIND (ANOVA test
F= 15.695 p=0.0001; Post hoc comparison: AD vs CTR
p=0.003; AD vs CIND p=0.0001; CIND vs CTR p=0.024).
MCP-1 plasma levels were also valuated in AD
patients stratified according to MMSE score. Severe AD
(MMSE score <14), showed apparently higher MCP-1
levels (51 pg/ml ±34) than mild AD (41 pg/ml ±27)
(MMSE score >14), but differences were not statistically
significant.
In addition, MCP-1 plasma levels were correlated
with the MCP-1 A-2518G promoter polymorphism.
Table 3 shows MCP-1 plasma levels in AD, CIND
and controls after the stratification for the three
MCP-1 A-2518G different genotypes. It is interesting
to note that AD patients and controls carrying AA
genotype showed lower MCP-1 plasma levels than
CIND (F=7.811 p=0.001). However, MCP-1 genotypes
or alleles did not affected MCP-1 plasma levels within
each population.Figure 2 MCP-1 plasma levels (pg/ml) in patient with AD, CIND
and Controls. ANOVA, F=15.695 p=0.0001Discussion
In AD brain, the presence of amyloid deposition, neurofib-
rillary tangles, activated microglia and astrocitosis may
stimulate a local and a chronic inflammatory process that
involves the synthesis and the release of numerous factors
such as cytokines, chemokines and inflammatory me-
diators [13]. However, systemic inflammation is also
detectable in peripheral blood of AD as illustrated by the
elevation of some acute phase proteins or cytokines [28].
In addition, a large number of genetic variations in
genes coding for pro- or anti inflammatory molecules
have been associated with the risk of dementia or cogni-
tive decline [4,5,29,30].
In the present study the distribution of MCP-1
A-2518G SNP in the promoter region of MCP-1 gene
and plasma levels of MCP-1 in AD or subjects with
preclinical AD were investigated.
Our findings suggested that the MCP-1 SNP promoter
was not a risk factor for AD being the SNP equally
distributed in AD patients and controls. Our results
confirmed data from different case-controls studies re-
porting no association between this SNP and the risk of
AD [21,24-26]. On the other hand, a different Italian
study by Pola et al. showed an increased representation
of GG genotype in AD patients [27]. Our data were not
able to confirm this latter study. Differences in SNP
distribution across case/controls studies might be ex-
plained by the great ethnic variability of this SNP, since
the G allele is found differentially present in Caucasian,
Americans or Asian population [23]. Differences between
present investigation and Pola’s study might be explained
by different clinical AD or CTR selection.
Then, we studied the distribution of MCP-1 A-2815G
SNP in a MCI population followed up for two years in
order to evaluated the effect of this SNP on the progres-
sion of the disease. No data on the effect of this SNP in
MCI/AD conversion is available in literature. The GTable 3 MCP-1 plasma levels (mean±s.d) in AD patients,
CIND and controls
AA AG GG Allele A Allele G P
AD (n=73) 44±32 41±28 39±6 42±29 41±26 0.910
CIND(n=20) 93±33 82±38 66.64±35 86±36 80±37 0.427
CTR(n=15) 44±22 94±113 74.37±50 62±69 91±101 0.697
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further cognitive deterioration and converted to AD.
However, this difference was not statistically significant.
This effect might be partially ascribed to the small size
of MCI population and further investigations are needed
to better understand the influence of this SNP in cogni-
tive deterioration and progression to AD.
High levels of pro-(or anti) inflammatory cytokines
and chemokines have been found associated with AD
[28]. The main role of these molecules and in particular
of MCP-1 is supported by the observation that this latter
molecule can induce chemotaxis of monocytes and
microglia, contributing to pathological gliosis associated
with AD [31,32]. Relevance of MCP-1 in AD was
suggested by data showing a significantly enhanced
immunoreactivity for MCP-1 in neurons, astrocytes and
microglia from AD brains [33]. Moreover, several studies
reported that MCP-1 plasma or CSF levels were higher
in AD patients or MCI than controls [19,20,31].
We found statistically differences in MCP-1 plasma
levels among AD, CIND and controls, being MCP-1
levels higher in CIND than those in AD patients and/or
controls.
In our study we measured MCP-1 levels by using BIO-
Plex multi Cytokines platform. Our results showed that
MCP-1 absolute levels, in pg/ml, from AD, CIND or
CTR, were lower than those found in other reports.
Different techniques for MCP-1 detection may partially
explain why we did not confirm increased MCP-1
plasma levels in AD. On the other hand, our data agree
with the only study that used the same detection system
used by us for MCP-1 levels [12]. Decreased level of
peripheral MCP-1 levels along with increased CSF con-
centration of this chemokyne in AD may suggest an
impaired MCP-1 turnover between these two compart-
ments. Such an alteration may be not present in pre
dementia conditions such as CIND since, increased
levels of blood MCP-1 levels were observed in this
population. However, further studies on a larger cohort
of CIND or MCI subjects are needed to better define the
role of blood MCP-1 in cognitive deterioration and AD
developing and the use of blood MCP-1 as a potential
marker for cognitive impairment.
MCP-1 expression might be under the control of A-
2518G promoter SNP. This is supported by a study
showing that the biallelic G/A polymorphism at position
2518 of the MCP-1 gene appears to influence the tran-
scriptional activity MCP-1 gene [22]. In particular G
allele seems to be associated with a higher MCP-1
production in a dose dependent manner where GG
homozygous produce more MCP-1 than that from G/A
heterozygous [22]. A previously reported study showed
that MCP-1 serum levels were increased in AD patients
positive for one or two G alleles [21]. Our data did notconfirm the above findings, since we did not find an
increase of MCP-1 levels in AD G carrier patients.
Accordingly, no effect of this SNP was observed on
MCP-1 plasma levels from CIND or controls.
Our study presents some limitations due to the selec-
tion of subject with a different kind of pre-dementia
condition: CIND and/or MCI. It is known that MCI,
with clinical assessed symptoms and risk factors well
described by Petersen RC, are likely to progress to AD
at a rate of approximately 12% per year [34]. On the
other hand, subjects with CIND show heterogeneous
risk factors only partially overlapping with those associ-
ated with MCI [35].
Data presented in our pilot study regarding the A-
2518G SNP distribution and MCP-1 plasma levels in
cognitive deterioration need to be replicated in a homoge-
neous and larger MCI population to better understand the
MCP-1 role in cognitve performance and deterioration.
Conclusion
Our findings suggest that MCP-1 G allele appears to
slightly influence MCI conversion to AD and that MCP-
1 plasma levels are increased in preclinical AD such as
subjects with CIND. These data implicate that MCP-1
genetic background and phenotypic expression might be
associated to early mechanisms associated with neurode-
generation leading to dementia. However, due to the
relatively small sample and the different pre-dementia
condition subjects included in the present study, our




The study included 291 patients with AD (mean
age=75.14±7.97), 88 patients with mild cognitive im-
pairment (MCI) (mean age=70.94±8.29), 20 CIND (mean
age=78.95±6.47) and 148 healthy subjects (mean age=
71.61±4.70 ).
Clinical diagnosis of probable AD was performed
according standard clinical procedures and followed the
NINCDS/ADRDA [36] and DSM-III-R criteria [37].
Diagnosis of probable AD was performed after patient
evaluation by two independent physicians and according
brain computerized tomography scan. Cognitive per-
formances and alterations were measured by the mini
mental state examination (MMSE).
AD patients were enrolled from Northern Italy at the
Department of Neuroscience of Castellanza University
(Milan, Italy).
MCI subjects were enrolled from the Department of
Neurology, University of Brescia, Northern Italy. Diagno-
sis of MCI was performed according to current clinical
criteria [38].
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belonged to the “Conselice study of brain aging” [39].
AD patients, MCI and CIND subjects and controls
were Caucasian and informed consent from each subject
or a relative of each AD patient was obtained.
DNA extraction and polymorphism detection
DNA extraction from peripheral blood leukocytes were
assessed as previously described [40].
The triallelic APOE ε2-4 polymorphism was assessed
by a polymerase chain reaction-based method as previ-
ously described [41].
The MCP-1 A-2518G promoter polymorphism
(rs699947) was detect by PCR reaction, amplification
with specific primers: Primer F 5’ CCGAGATGTTCCCA
GCACAG 3’, Primer R 5’ CTGCTTTGCTTGTGCCTC
TT 3’ with 5 min. at 96°C for the initial denaturation
and 30 cycles of 1 min. at 96°C, 1 min. at 60°C and
1.5 min. at 72°C. Then, 5 min. incubation at 72°C for
final extension was performed. The restriction enzyme
PvuII (MBI Fermentas, Italy; 5 U/sample) resolved three
different band patterns, according to the three different
genotypes; e.g. at 222 bp and 705 bp (GG genotype),
222 bp, 705 bp and 927bp (GA genotype) or only 927 bp
(AA genotype). The different bands pattern of the three
genotype after agarose gel running, was shown in
Figure 1.
MCP-1 plasma levels measurement
Bio-Plex Cytokine assay (Bio-Rad Laboratories, Hercules,
CA, USA) was used to measure MCP-1 plasma levels.
Assays were performed following the manufacturer’s
instructions (Multi beads assay BioPlex, BioRad). Briefly, a
sets of fluorescently dyed beads loaded with capture
monoclonal antibodies specific for MCP-1, were used.
Plasma samples (50 μl/well of four-fold diluted plasma) or
standards were incubated with 50 μl of pre-mixed beads
into the wells of a pre-wet 96 well microlitre plate.
After incubation and washing, 25 μl of fluorescent
detection antibody mixture were added for 30 min and
then the samples were washed and resuspended in assay
buffer. High standard curves ranging from 2098.48 to
0.62 pg/ml for MCP-1 was performed as suggested by
datasheet. Detection of MCP-1 levels was extrapolated
using Bio-Plex Cytokine software.
Statistical analysis
The Hardy-Weinberg equilibrium was verified for the
control group. Two-tailed Pearson’s χ2 exact test was
used to compare genotype and allele frequencies, the
level of statistical significance was set at less than 0.05. A
logistic regression model, adjusted for age and APOE ε4
allele was used to evaluate the effect of A-2518G MCP-1
SNP on the risk of AD, the risk of MCI conversion to AD.ANOVA test was used to compare the MCP-1 plasma
levels in the tested groups.
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